Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 23
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Eur J Cancer Prev ; 2020 Feb 07.
Artigo em Inglês | MEDLINE | ID: mdl-32039929

RESUMO

The relationship between hypertension and risk of colorectal cancer (CRC) is unclear. This meta-analysis aims to explore the association between them. Six databases were searched for studies published before August 2019. The pooled relative risk (RR) and 95% confidence intervals (CIs) were calculated to estimate the association between the hypertension and CRC risk. A total of 2841 potentially relevant articles were obtained, and 25 studies with a pooled 1.95 million participants were finally included in the meta-analysis. These results suggested a positive association between hypertension and risk of CRC with a pooled RR of 1.15 (95% CI: 1.08, 1.23). Male patients with hypertension had a 13% (95% CI: 1.06, 1.20) increased risk of CRC. The risk of colon cancer and rectal cancer in male patients was 1.17 (95% CI: 1.01, 1.36) and 1.35 (95% CI: 1.04, 1.74), respectively, while no association between hypertension and the risk of CRC in females was elucidated. This meta-analysis demonstrated that a positive association between hypertension and CRC exists, with male patients having a higher risk of developing CRC than female patients.

2.
Eur J Clin Pharmacol ; 76(2): 139-147, 2020 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-31748819

RESUMO

PURPOSE: The aim of this study was to explore the relationship between proton pump inhibitors use and the risk of dementia. METHODS: A comprehensive literature search was conducted in English and Chinese databases from origination to December 2018. The pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated with a random-effects model. Subgroup analyses and sensitivity analyses were also conducted. Cochran's Q test and the I2 statistic were used to evaluate the heterogeneity. Publication bias was assessed by Begg's test and Egger's test. RESULTS: Six studies were included, which contained a total of 166,146 participants. The overall result demonstrated a significant increase in dementia risk with proton pump inhibitors use (HR = 1.29, 95% CI = 1.12-1.49). In subgroup analyses, a significant association was detected between proton pump inhibitors use and the risk of dementia in Europe (HR = 1.46, 95% CI = 1.23-1.73) and among participants aged ≥ 65 years (HR = 1.39, 95% CI = 1.17-1.65). For the factor follow-up time ≥ 5 years, the pooled HR was 1.28 (95% CI = 1.12-1.46), demonstrating a 1.28-fold increase in the risk of dementia among proton pump inhibitors users. In the case of regional impact, participants from Europe showed an overall pooled HR estimate of 1.46 (95% CI = 1.23-1.73). There was no evidence of publication bias. CONCLUSIONS: The overall result of this meta-analysis supports the hypothesis that proton pump inhibitors increase the risk of dementia. Furthermore, high-quality cohort studies are needed to confirm these findings.

3.
J Clin Periodontol ; 47(2): 134-147, 2020 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-31697412

RESUMO

OBJECTIVE: To evaluate the association between periodontitis and the incidence and mortality of gastrointestinal cancer. METHOD: A comprehensive literature search was conducted to identify all relevant studies published prior to April 2019 according to the established inclusion criteria. The pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated with a random-effects model. RESULTS: We identified 10 studies with 26 estimates of the relationship between periodontitis and gastrointestinal cancer. The HR for the incidence of gastrointestinal cancer in periodontitis was 1.23 (95% CI: 1.10-1.37). Subgroup analyses showed that periodontitis was associated with an increased risk of gastrointestinal cancers in prospective cohort studies and high-quality studies, North American individuals, and individuals 18 years or older, as well as when the dental status was self-reported and when the study was adjusted for smoking. A meta-analysis of nine reports demonstrated that periodontitis was associated with increased mortality from gastrointestinal cancer (HR = 1.59, 95% CI: 1.16-2.16). Additionally, periodontitis was associated with mortality from pancreatic cancer (HR = 2.20, 95% CI: 1.44-3.37); thus, periodontitis may be a risk factor for pancreatic cancer. CONCLUSION: Our meta-analysis demonstrated that periodontitis may be a risk factor for gastrointestinal cancers. Additional prospective cohort studies are warranted to confirm these findings.

4.
J Sleep Res ; 29(1): e12876, 2020 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-31352687

RESUMO

Recently, emerging studies on the relationship between insomnia, the most common sleep disorder, and cancer have been published, but with inconsistent results. With the development of society and the accelerated pace of life, more and more people experience insomnia. Therefore, it is important to clarify the association. Relevant literature was obtained through a search of seven databases and supplementary searches. After a strict screening, eight cohort studies (seven prospective and one retrospective) involving 578,809 participants and 7,451 cancer events were incorporated into our analysis. The results demonstrate a modest 24% overall increased risk of cancer for individuals with insomnia in comparison to those without insomnia. The sensitivity analysis shows that the correlation between the two is stable. Subgroup analyses show that the risk of developing cancer was significantly higher in studies conducted in women (HR = 1.24; 95% CI, 1.01-1.53), but not in men (HR = 1.28; 95% CI, 0.90-1.80). Similarly, in terms of specific cancer types, the pooled HR was only significantly higher in thyroid cancer (HR = 1.36; 95% CI, 1.12-1.65) and not in other types of cancer (p > 0.05). Our findings suggest that insomnia may serve as an early warning sign of the onset of cancer and provide an opportunity for early detection and early intervention. Our findings should be treated with caution because of the limited number of included studies and potential bias. More additional studies are warranted to provide more information on the carcinogenic effect of insomnia.

5.
J Therm Biol ; 86: 102449, 2019 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-31789237

RESUMO

Heat stress induces oxidative stress, and reduces antioxidant defenses of birds, which may affect poultry-production performance. Dietary antioxidants may protect against heat stress. We evaluated the effect of increasing concentrations of dietary curcumin on antioxidant parameters of hens under high-temperature conditions for nine weeks. Roman laying hens (n = 336, 22 weeks old, 1420 g weight) were divided into three treatment groups. The first group served as a thermo-neutral control (kept at 25 ±â€¯1 °C). The second group was exposed to high temperatures (32 ±â€¯1 °C, 6 h/day), and fed a basal diet. The third group was further divided into five groups, and all were exposed to high temperatures (32 ±â€¯1 °C, 6 h/day) and provided a basal diet supplemented with 100, 150, 200, 250, 300 mg/kg curcumin (H1, H2, H3, H4, H5). All treatments included four replicates of 12 hens. Total superoxide dismutase (SOD) activity was significantly higher in H2 and H3 groups, and total antioxidant capacity (T-AOC) was higher in H2, H3, and H5 groups. Catalase (CAT) and glutathione peroxidase (GSH-Px) activities were significantly higher in the H3 group. Malondialdehyde concentrations were lower in curcumin supplemented hens compared to control groups hens. Hens in all curcumin treatment groups had slightly (but non-significantly) higher activities of CAT, SOD, GSH-Px, and T-AOC in liver, heart, and lung tissues, compared to heat stressed control group. It is concluded that dietary curcumin given to laying hens under heat stress may enhance their antioxidant status, and ameliorate stressful environmental conditions.

6.
Blood Press ; : 1-10, 2019 Nov 13.
Artigo em Inglês | MEDLINE | ID: mdl-31718311

RESUMO

Purposes: Many studies have indicated that orthostatic hypotension (OH) may be a risk factor for dementia and stroke, but the results have been inconsistent. To further ascertain the links between OH and cognition or stroke, a meta-analysis was performed.Methods: The Chinese Biomedical Database, PubMed, Web of Science, and the Cochrane Library database were searched (up to March 2019) to identify prospective cohort studies that examined the associations between OH and the risks of stroke and dementia among adult populations. Subgroup analyses and meta-regression analyses were conducted to identify sources of heterogeneity. We also performed Begg's test and Egger's test to assess publication bias.Results: A total of 3490 articles were identified, and 18 prospective observational cohort studies were ultimately included. Among these studies, eight prospective studies were about stroke, nine studies were about cognition and one study reported data about both stroke and dementia. Meta-analysis revealed an association between OH and worse cognition (hazard ratio (HR): 1.18, 95% confidence interval (CI): 1.03-1.35, I2 = 69.5%). For dementia, the pooled HR was 1.30, with 95% CI: 1.14-1.48, I2 = 31.0%. In addition, we found that OH was associated with a higher risk of stroke (HR: 1.36, 95% CI = 1.17-1.57, I2 = 67.3%). No publication bias was detected.Conclusion: This meta-analysis provides evidence that OH was associated with worse cognition. OH accounted for a 30% increase in the risk of dementia and a 36% increase in the risk of stroke.

8.
Animals (Basel) ; 9(8)2019 Jul 31.
Artigo em Inglês | MEDLINE | ID: mdl-31370305

RESUMO

Heat stress has a profound effect on poultry health and productivity. The present study evaluated whether feeding betaine could ameliorate long-term heat stress-induced impairment of productive performance in indigenous yellow-feathered broilers. A total of 240 five-week-old male broilers were randomly allocated to five treatments with six replicates of eight broilers each. The five treatments included a thermoneutral zone control group (TN, fed basal diet), a heat stress control group (HS, fed basal diet), and an HS control group supplemented 500, 1000, 2000 mg/kg betaine, respectively. The TN group was raised at 26 ± 1 °C during the whole study, HS groups exposed to 32 ± 1 °C for 8 h/day from 9:00 am to 17:00 pm. The results showed that heat stress decreased the body weight gain (BWG) and feed intake of broilers during 1-5, 6-10, and 1-10 weeks (p < 0.05). Dietary betaine tended to improve the BWG and feed intake of broilers under 5 weeks of heat stress (linear, p < 0.10), and betaine supplementation linearly increased the BWG and feed intake during 6-10 and 1-10 weeks (p < 0.05). Additionally, nitrogen retention was reduced by 5 weeks and 10 weeks of heat stress (p < 0.05), whereas dietary betaine could improve nitrogen retention in heat stressed broilers after both 5 and 10 weeks of heat stress (linear, p < 0.05). Moreover, this study observed that the trypsin activity of jejunum was decreased by 5 weeks of heat stress (p < 0.05), whereas betaine supplementation had quadratic effects on trypsin activity of jejunum in heat stressed broilers (p < 0.05). Furthermore, 10 weeks of heat stress induced a reduction of villus height of the duodenum and jejunum (p < 0.05), and decreased the villus height to crypt depth ratio of the jejunum (p < 0.05). Supplementation with betaine ameliorated the adverse effects of heat stress on these parameters (p < 0.05). Compared with the TN group, 10 weeks of heat stress reduced carcass and breast yield (p < 0.05) and betaine supplementation improved carcass and breast yield of heat stressed broilers (linear, p < 0.05). In conclusion, dietary supplementation of betaine could reduce the detrimental effects of long-term heat stress on growth performance, digestive function, and carcass traits in indigenous yellow-feathered broilers.

9.
J Hum Hypertens ; 33(9): 648-657, 2019 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-31363149

RESUMO

We performed this meta-analysis to assess the association between intensive systolic blood pressure (SBP)-lowering strategies and heart failure (HF). A comprehensive literature review was conducted using English and Chinese databases from their origination through April 2018. Random-effects models were used to calculate pooled relative risks and 95% confidence intervals. Nine randomized controlled trials including a total of 39,936 hypertensive patients were ultimately included in our meta-analysis. Pooled analysis of these nine trials showed that a treatment target of SBP ≤140 mmHg was associated with a significant reduction in HF risk (RR: 0.73, 95%CI: 0.62-0.87). Furthermore, the pooled analysis of prospective randomized controlled trials indicated a significant association between intensive lowering of SBP and HF risk (RR: 0.75, 95%CI: 0.62-0.90) and showed that intensive lowering of SBP could decrease risk of HF in patients without diabetes mellitus (RR: 0.69, 95%CI: 0.52-0.91) and in those ≥65 years old (RR: 0.72, 95%CI: 0.56-0.93), but this finding was not shown for patients with diabetes mellitus (RR: 0.81, 95%CI: 0.56-1.19) or in those <65 years old (RR: 0.81, 95%CI: 0.56-1.19). When intensive lowering of SBP achieved an SBP ≤ 120 mmHg, a pooled analysis indicated a positive association between SBP and HF risk (RR: 0.75, 95%CI: 0.63-0.89), and a pooled analyses showed that intensive lowering of SBP could decrease risk of HF in patients without diabetes mellitus (RR: 0.71, 95%CI: 0.51-0.98) and in those ≥65 years old (RR: 0.76, 95%CI: 0.58-0.98); however, this result was not found for patients with diabetes mellitus (RR: 0.81, 95%CI: 0.56-1.19) or those <65 years old (RR: 0.81, 95%CI: 0.56-1.19). The existing data support the results of a positive association between intensive SBP-lowering treatment and HF risk, especially for those patients without diabetes and those older than 65 years. However, additional prospective studies are still needed to confirm these associations.

10.
Pathol Res Pract ; 215(9): 152518, 2019 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-31303379

RESUMO

BACKGROUND: Caveolin-1 (CAV1) polymorphisms have been shown to correlated with breast cancer risk in previous studies. However, the role of CAV1 polymorphisms still remained indecisive, and dual functions of CAV1 was demonstrated in breast cancer development. Consequently, a meta-analysis to evaluate and summarize the association of the CAV1 polymorphisms with breast cancer susceptibility. MATERIAL AND METHODS: Extensive search was performed in PubMed, Web of Science, Google scholar, EMBASE.com, CNKI and Wanfang searching platform up to March 2019. The Newcastle-Ottawa Scale (NOS) were used to evaluate the quality of each study. The Odds ratios (ORs) and the 95% confidence intervals (CIs) were analyzed to evaluate the strength of the associations in five genetic models. Inter-study heterogeneity was quantified using the I-squared (I2) test. In addition, the Egger's test and Begg's test were applied to evaluate the publication bias. RESULTS: 4 case-control studies with 2115 cases and 2138 controls were enrolled into this analysis. There was a significant association between rs3807987 polymorphism of CAV1 and breast cancer in allele comparison (A vs. G: OR = 1.288, 95%CI = 1.162-1.428, P < 0.001), heterozygote comparison (AG vs. GG: OR= 1.422, 95%CI=1.233-1.639, P < 0.001), and dominant comparison (AA+AG vs. GG: OR=1.395, 95%CI=1.228-1.586, P < 0.001). A significant association of rs3807987 polymorphism in allele comparison (A vs. G: OR=1.238, 95%CI=1.109-1.383, P < 0.001), heterozygote comparison (AG VS. GG: OR=1.466, 95%CI=1.267-1.697, P < 0.05), and dominant comparison (AA+AG vs. GG: OR=1.384, 95%CI=1.209-1.585, P < 0.001) was also founded amongst Chinese population. A significant association between rs7804372 polymorphism and breast cancer amongst Chinese population in recessive comparison (AA vs. AT + TT: OR = 0.730, 95%CI = 0.567-0.940, P = 0.015) was identified. No significant association between breast cancer risk and rs1997623 was found. CONCLUSION: CAV1 rs3807987 and rs7804372 polymorphisms are associated with the change of breast cancer risk. More well-designed and large studies in various populations are needed to further elaborate these associations.

11.
J Clin Hypertens (Greenwich) ; 21(8): 1221-1227, 2019 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-31290595

RESUMO

The relationships between orthostatic hypotension (OH) and some kinds of cardiovascular disease are inconsistent among studies. This updated meta-analysis was conducted in hopes of producing progress on this topic. A systematic database search was performed in electronic databases, including the Chinese Biomedical Database (CBM), PubMed, Web of Science, and the Cochrane Library. Summary hazard ratio (HR) estimates with 95% confidence intervals (CIs) were calculated by a random-effects model. Statistical heterogeneity was assessed with Cochran's Q test and the I2 statistic. From 1462 potentially eligible records, 15 studies met the inclusion criteria. Subjects with OH had a high risk of heart failure (HF) and atrial fibrillation (AF) (pooled HR 1.34, 95% CI 1.17-1.52, P < 0.001 and pooled HR 1.51, 95% CI 1.28-1.79, P < 0.001, respectively). This meta-analysis also showed significant associations between OH and the risks of developing coronary heart disease (CHD) (pooled HR 1.44, 95% CI 1.18-1.75, P < 0.001) and myocardial infarction (MI) (pooled HR 1.52, 95% CI 1.12-2.06, P = 0.008). Our study suggests that OH is positively associated with high risks of HF and AF. Moreover, it may be related to high risks of CHD and MI.

12.
J Coll Physicians Surg Pak ; 29(6): S65-S67, 2019 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-31142427

RESUMO

Here, we present a case of a 25-year Chinese female who was diagnosed with non-functional adrenocortical adenoma containing myelolipoma with hypertension as the only symptom. Serum levels of cortisol, aldosterone, angiotensin I/II and renin activity were normal. Myelolipoma is a benign, non-functioning retroperitoneal tumour occurring predominantly in the adrenal gland and relatively uncommon. With the advancement of radiological studies, the incidental detection of myelolipoma has been noted. However, the coexistence of adrenal myelolipoma and adrenal adenoma still remains extremely rare. Though usually benign, the later may present with endocrine dysfunction, such as Cushing's syndrome, and requires proper management. Surgical resection is reserved for symptomatic tumours or large myelolipoma (>7 cm in size). The final diagnosis mainly relies on pathological examination. The left adrenal mass was completely removed via retroperitoneal laparoscopic approach. Postoperative recovery was uneventful and her blood pressure (BP) readings were normal. At 15 months follow-up, the patient was normotensive and there was no recurrence of tumour.


Assuntos
Neoplasias das Glândulas Suprarrenais/cirurgia , Adrenalectomia , Adenoma Adrenocortical/diagnóstico , Adenoma Adrenocortical/cirurgia , Hipertensão/complicações , Hipertensão/etiologia , Mielolipoma/cirurgia , Neoplasias Primárias Múltiplas/cirurgia , Neoplasias das Glândulas Suprarrenais/complicações , Neoplasias das Glândulas Suprarrenais/diagnóstico , Glândulas Suprarrenais/diagnóstico por imagem , Adenoma Adrenocortical/complicações , Adulto , Pressão Sanguínea/fisiologia , Feminino , Humanos , Laparoscopia , Mielolipoma/complicações , Mielolipoma/diagnóstico , Tomografia Computadorizada por Raios X , Resultado do Tratamento
13.
Sleep Breath ; 23(4): 1047-1057, 2019 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-30903565

RESUMO

Previous epidemiological investigations have evaluated the association between gout, serum uric acid levels, and obstructive sleep apnea syndrome (OSAS), but with inconsistent results. We conducted this meta-analysis aiming at providing clear evidence about whether OSAS patients have higher serum uric acid levels and more susceptible to gout. Relevant studies were identified via electronic databases from inception to December 17, 2018. Study selection was conducted according to predesigned eligibility criteria, and two authors independently extracted data from included studies. The hazard ratio (HR) and weighted mean difference (WMD) and their corresponding 95% confidence interval (CI) were derived using random-effects models. We conducted meta-, heterogeneity, publication bias, sensitivity, and subgroup analyses. Eighteen studies, involving a total of 157,607 individuals (32,395 with OSAS, 125,212 without OSAS) and 12,262 gout cases, were included. Results show that serum uric acid levels are elevated in patients with OSAS (WMD = 52.25, 95% CI 36.16-64.33); OSAS did not reach statistical significance as a predictor of gout (but there was a trend, HR = 1.25, 95% CI 0.91-1.70) and that the association between OSAS and serum uric acid was quite robust. OSAS may be a potential risk factor for hyperuricemia and the development of gout and thus, effective OSAS therapy may present as a valuable preventive measure against gout. Still, it is vital to undertake clinical studies with better designing to corroborate these associations and shed new light on it.

14.
Pancreas ; 48(2): 142-150, 2019 02.
Artigo em Inglês | MEDLINE | ID: mdl-30640225

RESUMO

OBJECTIVE: The aim of this study was to explore the relationship between statin use and the risk of pancreatic cancer. METHODS: Electronic databases were searched to identify relevant studies published until January 2018. The pooled relative risks (RRs) and 95% confidence intervals (CIs) were calculated with random-effects model. Subgroup analyses and sensitivity analysis were also conducted. Cochran Q test and I(2) statistic were used to evaluate the heterogeneity. RESULTS: Twenty-six studies were included that contained more than 3 million participants and 170,000 pancreatic cancer patients. The overall result demonstrated a significant decrease in pancreatic cancer risk with statin use (RR, 0.84; 95% CI, 0.73-0.97; P = 0.000; I(2) = 84.4%). In subgroup analyses, nonsignificant association was detected between long-term statin use and the risk of pancreatic cancer (RR, 0.98; 95% CI, 0.86-1.11; P = 0.718; I(2) = 0.0%). Meanwhile, there was nonsignificant association between the use of lipophilic statins and the risk of pancreatic cancer (RR, 0.98; 95% CI, 0.84-1.15; P = 0.853; I(2) = 27.2%). No publication bias was found in this meta-analysis. CONCLUSIONS: The overall result of this meta-analysis supports the hypothesis that statins have a protective effect on pancreatic cancer. Furthermore, high-quality randomized clinical trials and cohort studies are needed to confirm these findings.


Assuntos
Inibidores de Hidroximetilglutaril-CoA Redutases/uso terapêutico , Neoplasias Pancreáticas/prevenção & controle , Humanos , Neoplasias Pancreáticas/diagnóstico , Neoplasias Pancreáticas/epidemiologia , Prognóstico , Fatores de Proteção , Medição de Risco , Fatores de Risco
15.
Mol Carcinog ; 58(6): 933-943, 2019 06.
Artigo em Inglês | MEDLINE | ID: mdl-30675923

RESUMO

NEK5, a contraction of NIMA Related Kinase 5, has been shown to regulate the centrosome integrity of cells though; it has been little described in cancer. Herein, to explore the clinicopathological meaning of NEK5 expression in breast cancer, immunohistochemistry was performed to detect the expression of NEK5 on tissue blocks, totaling 203 cases. Quantitative real-time PCR (qRT-PCR) was used to evaluate NEK5 mRNA expression with 30 cases of fresh tissues. To observe the function of NEK5 in the growth of breast cancer cells, both MTT and xenografted nude mice were performed. And Transwell assay was employed to observe the variation of migration and invasion. It was shown that up-regulated NEK5 was significantly associated with tumor progression and poor overall prognosis; and that silencing of NEK5 can significantly suppress the proliferation both in vivo and in vitro, inhibiting migration, and invasion. To get insight into the underlying mechanism by which NEK5 operates in proliferation of breast cancer cells, we showed that NEK5 can up-regulate Cyclin A2 and down-regulate Cyclin D1, Cyclin D3, and Cyclin E1 expression. Additionally, Cyclin A2 was also identified as a novel interacting protein for NEK5. Taking together, we firstly defined the oncogenic role of NEK5 in breast cancer that was related to proliferation, supporting that NEK5 might be used a new therapeutic target in breast cancer.


Assuntos
Neoplasias da Mama/patologia , Ciclina A2/metabolismo , Quinases Relacionadas a NIMA/genética , Quinases Relacionadas a NIMA/metabolismo , Regulação para Cima , Animais , Neoplasias da Mama/genética , Neoplasias da Mama/metabolismo , Linhagem Celular Tumoral , Progressão da Doença , Feminino , Regulação Neoplásica da Expressão Gênica , Humanos , Células MCF-7 , Camundongos , Camundongos Nus , Transplante de Neoplasias , Prognóstico
16.
Int J Geriatr Psychiatry ; 33(12): 1541-1547, 2018 12.
Artigo em Inglês | MEDLINE | ID: mdl-30247788

RESUMO

OBJECTIVES: As for the association between orthostatic hypotension (OH) and dementia, results of published studies are inconsistent; therefore, current substantive conclusions have yet been obtained. This meta-analysis was conducted in hopes of producing progress in this topic. METHODS: A systematic database search was performed towards electronic databases including Chinese Biomedical Database, PubMed, Web of Science, Wiley Online Library, ScienceDirect, and the Cochrane Library. Five prospective cohort studies were included. Summary hazard ratio (HR) estimates with 95% confidence intervals (CIs) were calculated by random-effects model. Statistical heterogeneity was assessed with the Cochran Q test and I2 statistic. A sensitivity analysis was also conducted in this meta-analysis. RESULTS: A 22.4% higher prevalence of dementia in subjects with OH was obtained (adjusted pooled HR was 1.224; 95% CI: 1.106-1.354; P < .001). This meta-analysis also showed significant associations between OH and 2 dementia subtypes: Alzheimer disease (adjusted pooled HR was 1.175; 95% CI: 1.022-1.351; P = .023) and Vascular dementia (adjusted pooled HR was 1.403; 95% CI: 1.042-1.889; P = .026), respectively. CONCLUSIONS: Orthostatic hypotension is positively associated with the overall prevalence of dementia, and it may contribute to the prevalence of Alzheimer disease and Vascular dementia as well.


Assuntos
Doença de Alzheimer/epidemiologia , Demência Vascular/epidemiologia , Hipotensão Ortostática/complicações , Doença de Alzheimer/complicações , Demência Vascular/complicações , Humanos , Prevalência , Modelos de Riscos Proporcionais , Estudos Prospectivos
17.
J Clin Periodontol ; 45(9): 1025-1033, 2018 09.
Artigo em Inglês | MEDLINE | ID: mdl-29974484

RESUMO

OBJECTIVE: While some individual studies have suggested an association between periodontal disease and breast cancer, there has not been a formal meta-analysis that collates the existing evidence supporting the hypothesis that periodontal disease leads to a higher risk of developing breast cancer. Accordingly, this meta-analysis was conducted. METHODS: Relevant studies published until April 2018 were retrieved and were screened according to established inclusion criteria. Risk ratios (RRs) with 95% confidence intervals (CIs) were calculated to assess the association between periodontal disease and the risk of breast cancer and fixed effect models were used according to the results of the heterogeneity test. RESULTS: Eight studies, involving 168,111 individuals, were identified as having explored the association between periodontal disease and breast cancer. Summary estimates in view of adjusted data showed that periodontal disease did increase susceptibility to breast cancer (RR = 1.18, 95%CI: 1.11-1.26, I2  = 17.6%), with robust results confirmed by sensitivity analysis. CONCLUSION: Our results provided evidence of a modest positive association between periodontal disease and breast cancer. Implementation of practical measures to prevent and treat periodontal disease is of great public health significance. Moreover, additional studies are recommended to explore this topic in more detail.


Assuntos
Neoplasias da Mama , Doenças Periodontais , Humanos , Estudos Observacionais como Assunto , Razão de Chances
18.
Mol Diagn Ther ; 22(4): 397-407, 2018 08.
Artigo em Inglês | MEDLINE | ID: mdl-29909568

RESUMO

INTRODUCTION: The association between the checkpoint kinase 2*1100delC (CHEK2*1100delC) and breast cancer has been extensively explored. OBJECTIVE: In light of the recent publication of studies on these specific findings, particularly regarding male patients with breast cancer, we performed an updated meta-analysis to investigate a more reliable estimate. METHODS: This meta-analysis included 26 published studies selected in a search of electronic databases up to January 2018, including 118,735 breast cancer cases and 195,807 controls. Odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the association between 1100delC and breast cancer. RESULTS: Meta-analysis results suggested that 1100delC contributed to an increased breast cancer risk in overall populations (OR 2.89; 95% CI 2.63-3.16). Subgroup analysis found ORs of 3.13 (95% CI 1.94-5.07) for male breast cancer, 2.88 (95% CI 2.63-3.16) for female breast cancer, 2.87 (95% CI 1.85-4.47) for early-onset breast cancer, 2.92 (95% CI 2.65-3.22) for invasive breast cancer, and 3.21 (95% CI 2.41-4.29) for familial breast cancer. The sensitivity analysis suggested that results of this meta-analysis were generally robust. CONCLUSION: CHEK2*1100delC is associated with an increased risk of both female and male breast cancer.


Assuntos
Neoplasias da Mama/etiologia , Quinase do Ponto de Checagem 2/genética , Estudos de Associação Genética , Predisposição Genética para Doença , Deleção de Sequência , Alelos , Biomarcadores Tumorais , Neoplasias da Mama/metabolismo , Neoplasias da Mama/patologia , Estudos de Casos e Controles , Feminino , Genótipo , Heterozigoto , Humanos , Masculino , Razão de Chances , Viés de Publicação , Medição de Risco , Fatores de Risco
19.
Food Chem Toxicol ; 119: 334-341, 2018 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-29458160

RESUMO

Due to the ability of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) to induce cancer cell apoptosis selectively, TRAIL has attracted significant interest in the treatment of cancer. However, although TRAIL triggers apoptosis in a broad range of cancer cells, most primary cancers are often intrinsically TRAIL-resistant, or can acquire resistance after TRAIL treatment, evocating new strategies to overcome TRAIL resistance. Gambogic acid (GA), an active constituent of Garcinia Hanburyi (Teng Huang in Chinese), has been applied for thousands of years for medicinal uses, however, the potential effect of GA in combating cancer resistance remains poorly investigated. In this study, we found that GA could increase the sensitivity of breast cancer cells to TRAIL and enhance TRAIL-induced apoptosis. GA cooperated with TRAIL to decrease the levels of anti-apoptotic proteins and activate Bid (BH3 interacting-domain death agonist) to promote the crosstalk of extrinsic and intrinsic apoptotic signaling, rather than increasing the expression of TRAIL receptors DR4 and DR5. These findings may open a new window in the treatment of breast cancer using TRAIL in combination with GA.


Assuntos
Apoptose/efeitos dos fármacos , Neoplasias da Mama/patologia , Transdução de Sinais/efeitos dos fármacos , Ligante Indutor de Apoptose Relacionado a TNF/fisiologia , Xantonas/farmacologia , Apoptose/fisiologia , Neoplasias da Mama/metabolismo , Caspases/metabolismo , Linhagem Celular Tumoral , Resistencia a Medicamentos Antineoplásicos , Ativação Enzimática , Feminino , Humanos , Mitocôndrias/efeitos dos fármacos , Mitocôndrias/enzimologia
20.
Int J Gynaecol Obstet ; 140(2): 146-152, 2018 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-29094354

RESUMO

BACKGROUND: Research into the effects of breast cancer on delivery outcomes has generated inconsistent findings. OBJECTIVES: To pool data from existing observational studies of the effect of breast cancer on preterm delivery and low delivery weight. SEARCH STRATEGY: A systematic literature search of PubMed, Embase, and Web of Science databases using keywords including, "breast cancer" and "birth outcome" up to March 7, 2017, was performed. SELECTION CRITERIA: Observational studies of the effect of breast cancer on delivery outcomes were included. DATA COLLECTION AND ANALYSIS: Articles were reviewed independently by two authors and data were extracted. Risk ratios and 95% confidence intervals were calculated. MAIN RESULTS: Preterm delivery data were included from seven studies including 6 687 579 patients and low delivery weight data were retrieved from five studies including 6 687 103 patients. Maternal breast cancer was associated with an increased risk of preterm delivery (pooled risk ratio 1.82, 95% confidence interval 1.44-2.30) and low delivery weight (pooled risk ratio 1.41, 95% confidence interval 1.15-1.74). No publication bias was detected in the meta-analysis. CONCLUSIONS: The present meta-analysis demonstrated that maternal breast cancer was associated with increased risk of preterm delivery and low delivery weight.


Assuntos
Neoplasias da Mama/complicações , Recém-Nascido de Baixo Peso , Complicações Neoplásicas na Gravidez , Nascimento Prematuro/epidemiologia , Sobreviventes de Câncer/estatística & dados numéricos , Estudos de Casos e Controles , Feminino , Humanos , Recém-Nascido , Estudos Observacionais como Assunto , Gravidez , Resultado da Gravidez , Estudos Retrospectivos , Risco
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA